We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 76

Global privacy & data security update vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


Glaxosmithkline fined $3 billion for illegal marketing of drugs
  • Jones Day
  • USA
  • July 13 2012

GSK has agreed a settlement with the DoJ whereby it will pay $3 billion for failings in the methods used to market its products


Global Privacy & Cybersecurity Update Vol. 11 - September 2016
  • Jones Day
  • Australia, European Union, France, USA
  • September 12 2016

Multinational companies have faced new developments over the past year in the area of EU data protection law, from the invalidation of the U.S.-EU


DOJ-HHS Medicare Strike Force charges 91 individuals in eight cities
  • Jones Day
  • USA
  • February 6 2012

In September 2011, a nationwide takedown by Medicare Fraud Strike Force operations in eight cities (Detroit, Miami, Houston, Baton Rouge, Los Angeles, Dallas, Brooklyn, and Chicago) resulted in charges against 91 individuals for their alleged participation in schemes involving approximately $295 million in false billing


Federal agencies expand outreach and ramp up resources for health care enforcement
  • Jones Day
  • USA
  • April 21 2011

HHS and the Department of Justice (DOJ) have initiated several programs to enhance awareness of health care compliance requirements and enforcement efforts and to significantly increase the resources devoted to detecting fraud and abuse in the health care industry


The rise of parallel proceedings in health care fraud investigations: how to tell when you’re a target
  • Jones Day
  • USA
  • April 11 2014

When Dewey & LeBoeuf lawyer Zachary Warren was indicted for fraud recently, his surprised reaction made headlines.1 Warren, The New York Times


U.S. Supreme Court rules that a drug’s adverse event reports may be material to investors even though not "statistically significant"
  • Jones Day
  • USA
  • March 28 2011

On March 22, 2011, the U.S. Supreme Court issued its long-awaited opinion in Matrixx Initiatives, Inc. v. Siracusano (No. 09-1156


SEC alleges securities fraud by biopharmaceutical company and executives
  • Jones Day
  • USA
  • September 6 2011

On August 1, 2011, the SEC brought suit against Immunosyn Corporation, Argyll Biotechnologies LLC, and four executives, alleging that they had committed securities fraud related to misleading statements regarding the status of regulatory approvals during 200610


House holds hearings on bill to simplify criminal code
  • Jones Day
  • USA
  • February 6 2012

On December 13, 2011, the House Judiciary Committee's Subcommittee on Crime, Terrorism, and Homeland Security held a hearing on H.R. 1823 (Criminal Code Modernization and Simplification Act of 2011), a bill that would revise and reorganize the federal criminal code


OIG advises Connecticut and Iowa that their false claims laws meet the requirements to receive an additional share in recovery
  • Jones Day
  • USA
  • February 6 2012

On November 15, 2011, the Connecticut false claims law became the first state law to meet or exceed the provisions of the federal FCA as recently amended